Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 9/2016

01-09-2016

Comprehensive investigation of aberrant microRNA profiling in bladder cancer tissues

Authors: Yanping Wei, Rongquan He, Yuzhuang Wu, Binliang Gan, Peirong Wu, Xiaohui Qiu, Aihua Lan, Gang Chen, Qiuyan Wang, Xinggu Lin, Yingchun Chen, Zengnan Mo

Published in: Tumor Biology | Issue 9/2016

Login to get access

Abstract

There has been accumulative evidence that microRNAs (miRNAs) play essential roles in the tumorigenesis and progression of bladder cancer. However, individual studies and small sample size caused discrepant outcomes. Thus, the current study focused on a comprehensive profiling of all differentially expressed miRNAs in a total of 519 bladder cancer tissue samples, based on miRNA microarray data. Altogether, 11 prioritized miRNAs stated by 21 published microarray datasets, including five down-regulated (miR-133a-3p, miR-1-3p, miR-99a-5p, miR-490-5p, and miR-133b) and six up-regulated candidate miRNAs (miR-182-5p, miR-935, miR-518e-3p, miR-573, miR-100-3p, and miR-3171) were analyzed with vote-counting strategy and a Robust Rank Aggregation method. Subsequently, miRNA in silico target prediction and potential pathway enrichment analysis were performed to investigate the prospective molecular mechanism of miRNAs in the tumorigenesis of bladder cancer. We found that most of the relative pathways of the aberrantly expressed miRNAs found in the current study were closely correlated with different biological processes, cellular components, molecular functions, cancer pathogeneses, and some cell signalings, such as Wnt signaling, insulin/IGF, PI3 kinase, and FGF signaling pathways. Hence, a comprehensive overview on the miRNA expression pattern in bladder cancer tissues was gained by the current study. These miRNAs might be involved in the tumorigenesis and deterioration of bladder cancer.
Literature
1.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer J Int Cancer. 2015;136(5):E359–86.CrossRef
2.
3.
Scheffer AR, Holdenrieder S, Kristiansen G, von Ruecker A, Muller SC, Ellinger J. Circulating microRNAs in serum: novel biomarkers for patients with bladder cancer? World J Urol. 2014;32(2):353–8.CrossRefPubMed
4.
Wang Z, Cai Q, Jiang Z, Liu B, Zhu Z, Li C: Prognostic role of microRNA-21 in gastric cancer: a meta-analysis. Med Sci Monit Int Med J Exp Clin Res 2014, 20:1668–1674.
5.
Chen QW, Zhu XY, Li YY, Meng ZQ. Epigenetic regulation and cancer (review). Oncol Rep. 2014;31(2):523–32.PubMed
6.
Jin D, Fang Y, Li Z, Chen Z, Xiang J. Epithelial-mesenchymal transitionassociated microRNAs in colorectal cancer and drug-targeted therapies (review). Oncol Rep. 2015;33(2):515–25.PubMed
7.
Lyra-Gonzalez I, Flores-Fong LE, Gonzalez-Garcia I, Medina-Preciado D, Armendariz-Borunda J. MicroRNAs dysregulation in hepatocellular carcinoma: insights in genomic medicine. World J Hepatol. 2015;7(11):1530–40.CrossRefPubMedPubMedCentral
8.
9.
Pan F, Mao H, Deng L, Li G, Geng P. Prognostic and clinicopathological significance of microRNA-21 overexpression in breast cancer: a meta-analysis. Int J Clin Exp Pathol. 2014;7(9):5622–33.PubMedPubMedCentral
10.
Zheng RL, Jiang YJ, Wang X. Role of microRNAs on therapy resistance in non-Hodgkin’s lymphoma. Int J Clin Exp Med. 2014;7(11):3818–32.PubMedPubMedCentral
11.
Kozomara A. Griffiths-Jones S: miRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 2014;42(Database issue):D68–73.CrossRefPubMed
12.
Ding M, Li Y, Wang H, Lv Y, Liang J, Wang J, Li C. Diagnostic value of urinary microRNAs as non-invasive biomarkers for bladder cancer: a meta-analysis. Int J Clin Exp Med. 2015;8(9):15432–40.PubMedPubMedCentral
13.
Chen L, Cui Z, Liu Y, Bai Y, Lan F. MicroRNAs as biomarkers for the diagnostics of bladder cancer: a meta-analysis. Clin Lab. 2015;61(8):1101–8.PubMed
14.
Ouyang H, Zhou Y, Zhang L, Shen G. Diagnostic value of MicroRNAs for urologic cancers: a systematic review and meta-analysis. Medicine. 2015;94(37):e1272.CrossRefPubMedPubMedCentral
15.
Cheng Y, Deng X, Yang X, Li P, Zhang X, Li P, Tao J, Lu Q, Wang Z. Urine microRNAs as biomarkers for bladder cancer: a diagnostic meta-analysis. OncoTargets Ther. 2015;8:2089–96.
16.
Shi Z, Wei Q, Zhang M, She J. MicroRNAs in bladder cancer: expression profiles, biological functions, regulation, and clinical implications. Crit Rev Eukaryot Gene Expr. 2014;24(1):55–75.CrossRefPubMed
17.
Zhou H, Tang K, Xiao H, Zeng J, Guan W, Guo X, Xu H, Ye Z. A panel of eight-miRNA signature as a potential biomarker for predicting survival in bladder cancer. J Exp Clin Cancer Res CR. 2015;34:53.CrossRefPubMed
18.
Ichimi T, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Kawahara K, Toki K, Kawakami K, Nishiyama K, et al. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer J Int Cancer. 2009;125(2):345–52.CrossRef
19.
Song T, Xia W, Shao N, Zhang X, Wang C, Wu Y, Dong J, Cai W, Li H. Differential miRNA expression profiles in bladder urothelial carcinomas. Asian Pac J Cancer Prev: APJCP. 2010;11(4):905–11.PubMed
20.
Yoshino H, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N, Nakagawa M. The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. Br J Cancer. 2011;104(5):808–18.CrossRefPubMedPubMedCentral
21.
Yamasaki T, Yoshino H, Enokida H, Hidaka H, Chiyomaru T, Nohata N, Kinoshita T, Fuse M, Seki N, Nakagawa M. Novel molecular targets regulated by tumor suppressors microRNA-1 and microRNA-133a in bladder cancer. Int J Oncol. 2012;40(6):1821–30.PubMed
22.
Pignot G, Cizeron-Clairac G, Vacher S, Susini A, Tozlu S, Vieillefond A, Zerbib M, Lidereau R, Debre B. Amsellem-Ouazana D et al: microRNA expression profile in a large series of bladder tumors: identification of a 3-miRNA signature associated with aggressiveness of muscle-invasive bladder cancer. Int J Cancer J Int Cancer. 2013;132(11):2479–91.CrossRef
23.
Wang T, Yuan J, Feng N, Li Y, Lin Z, Jiang Z, Gui Y. Hsa-miR-1 downregulates long non-coding RNA urothelial cancer associated 1 in bladder cancer. Tumour Biol J Int Soc Oncodev Biol Med. 2014;35(10):10075–84.CrossRef
24.
Du M, Shi D, Yuan L, Li P, Chu H, Qin C, Yin C, Zhang Z, Wang M. Circulating miR-497 and miR-663b in plasma are potential novel biomarkers for bladder cancer. Sci Report. 2015;5:10437.CrossRef
25.
Yoshino H, Enokida H, Chiyomaru T, Tatarano S, Hidaka H, Yamasaki T, Gotannda T, Tachiwada T, Nohata N, Yamane T, et al. Tumor suppressive microRNA-1 mediated novel apoptosis pathways through direct inhibition of splicing factor serine/arginine-rich 9 (SRSF9/SRp30c) in bladder cancer. Biochem Biophys Res Commun. 2012;417(1):588–93.CrossRefPubMed
26.
Feng Y, Kang Y, He Y, Liu J, Liang B, Yang P. Yu Z: microRNA-99a acts as a tumor suppressor and is down-regulated in bladder cancer. BMC Urol. 2014;14:50.CrossRefPubMedPubMedCentral
27.
Zhang DZ, Lau KM, Chan ES, Wang G, Szeto CC, Wong K, Choy RK, Ng CF. Cell-free urinary microRNA-99a and microRNA-125b are diagnostic markers for the non-invasive screening of bladder cancer. PLoS One. 2014;9(7):e100793.CrossRefPubMedPubMedCentral
28.
Xu Z, Yu YQ, Ge YZ, Zhu JG, Zhu M, Zhao YC, Xu LW, Yang XB, Geng LG, Dou QL, et al. MicroRNA expression profiles in muscle-invasive bladder cancer: identification of a four-microRNA signature associated with patient survival. Tumour Biol J Int Soc Oncodev Biol Med. 2015;36(10):8159–66.CrossRef
29.
Wu D, Zhou Y, Pan H, Zhou J, Fan Y. Qu P: microRNA-99a inhibiting cell proliferation, migration and invasion by targeting fibroblast growth factor receptor 3 in bladder cancer. Oncol Lett. 2014;7(4):1219–24.PubMedPubMedCentral
30.
Lan G, Yang L, Xie X, Peng L, Wang Y. MicroRNA-490-5p is a novel tumor suppressor targeting c-FOS in human bladder cancer. Arch Med Sci AMS. 2015;11(3):561–9.CrossRefPubMed
31.
Li S, Xu X, Xu X, Hu Z, Wu J, Zhu Y, Chen H, Mao Y, Lin Y, Luo J, et al. MicroRNA-490-5p inhibits proliferation of bladder cancer by targeting c-Fos. Biochem Biophys Res Commun. 2013;441(4):976–81.CrossRefPubMed
32.
Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, Jiang Z, Zhang Z, Yang R, Chen J, et al. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. PLoS One. 2011;6(3):e18286.CrossRefPubMedPubMedCentral
33.
Chen XN, Wang KF, Xu ZQ, Li SJ, Liu Q, Fu DH, Wang X, Wu B. MiR-133b regulates bladder cancer cell proliferation and apoptosis by targeting Bcl-w and Akt1. Cancer Cell Int. 2014;14:70.CrossRefPubMedPubMedCentral
34.
Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, Fristrup N, Jensen JL, Andersen CL, Zieger K, et al. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Cancer Res. 2009;69(11):4851–60.CrossRefPubMed
35.
Zhou Y, Wu D, Tao J, Qu P, Zhou Z, Hou J. MicroRNA-133 inhibits cell proliferation, migration and invasion by targeting epidermal growth factor receptor and its downstream effector proteins in bladder cancer. Scand J Urol. 2013;47(5):423–32.CrossRefPubMed
36.
Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, Yin C. Zhang W: microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep. 2012;27(6):1967–75.PubMed
37.
Kriebel S, Schmidt D, Holdenrieder S, Goltz D, Kristiansen G, Moritz R, Fisang C, Muller SC, Ellinger J. Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer. PLoS One. 2015;10(1):e0117284.CrossRefPubMedPubMedCentral
38.
Hirata H, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y, Dahiya R. Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One. 2012;7(11):e51056.CrossRefPubMedPubMedCentral
39.
Mengual L, Lozano JJ, Ingelmo-Torres M, Gazquez C, Ribal MJ, Alcaraz A. Using microRNA profiling in urine samples to develop a non-invasive test for bladder cancer. Int J Cancer J Int Cancer. 2013;133(11):2631–41.
40.
Jiang X, Du L, Wang L, Li J, Liu Y, Zheng G, Qu A, Zhang X, Pan H, Yang Y, et al. Serum microRNA expression signatures identified from genome-wide microRNA profiling serve as novel noninvasive biomarkers for diagnosis and recurrence of bladder cancer. Int J Cancer J Int Cancer. 2015;136(4):854–62.CrossRef
Metadata
Title
Comprehensive investigation of aberrant microRNA profiling in bladder cancer tissues
Authors
Yanping Wei
Rongquan He
Yuzhuang Wu
Binliang Gan
Peirong Wu
Xiaohui Qiu
Aihua Lan
Gang Chen
Qiuyan Wang
Xinggu Lin
Yingchun Chen
Zengnan Mo
Publication date
01-09-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 9/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-016-5121-z

Other articles of this Issue 9/2016

Tumor Biology 9/2016 Go to the issue

Original Article

Protein phosphatase 4 catalytic subunit is overexpressed in glioma and promotes glioma cell proliferation and invasion

Original Article

Primary cultures of human colon cancer as a model to study cancer stem cells

Original Article

Efficient isolation and proteomic analysis of cell plasma membrane proteins in gastric cancer reveal a novel differentiation and progression related cell surface marker, R-cadherin

Original Article

Cytotoxicity of withasteroids: withametelin induces cell cycle arrest at G2/M phase and mitochondria-mediated apoptosis in non-small cell lung cancer A549 cells

Original Article

Secretome of tumor-associated leukocytes augment epithelial-mesenchymal transition in positive lymph node breast cancer patients via activation of EGFR/Tyr845 and NF-κB/p65 signaling pathway

Original Article

Assessment of PARP protein expression in epithelial ovarian cancer by ELISA pharmacodynamic assay and immunohistochemistry
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits